Core Viewpoint - Kiniksa Pharmaceuticals International will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, highlighting its focus on therapeutic medicines for unmet medical needs [1]. Company Overview - Kiniksa is a commercial-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases [3]. - The company specializes in immune-modulating assets that target underserved cardiovascular and autoimmune conditions, aiming for differentiation based on strong biological rationale or validated mechanisms [3]. Event Details - The presentation will take place at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) [1]. - A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible approximately 48 hours after the event [2].

Group 1 - Kiniksa Pharmaceuticals will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on November 19, 2024, at 12:00 p.m. GMT [1] - A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible within approximately 48 hours after the event [2] - Kiniksa is a commercial-stage biopharmaceutical company focused on developing therapeutic medicines for patients with significant unmet medical needs, particularly in cardiovascular and autoimmune conditions [3]

Financial Performance - Product revenue for the three months ended September 30, 2024, was $112.2 million, a 65% increase from $64.8 million in the same period of 2023[18]. - Total revenue for the nine months ended September 30, 2024, reached $300.7 million, compared to $186.9 million for the same period in 2023, reflecting a 60% increase[18]. - The net loss for the three months ended September 30, 2024, was $12.7 million, compared to a net loss of $13.9 million for the same period in 2023[18]. - Net loss for the nine months ended September 30, 2024, was $34,305,000, compared to a net loss of $11,153,000 for the same period in 2023[22]. - Basic and diluted net loss attributable to ordinary shareholders for the three months ended September 30, 2024, was $(12,693) million, compared to $(13,855) million for the same period in 2023[115]. - The company reported a net loss of $34.3 million for the nine months ended September 30, 2024, compared to a net loss of $11.2 million in the same period of 2023[192]. Revenue Sources - Product revenue from ARCALYST for the three months ended September 30, 2024, was $112,214, representing a 73% increase from $64,802 in the same period of 2023[55]. - For the nine months ended September 30, 2024, product revenue was $294,493, up 82% from $161,956 in the prior year[55]. - Net revenue from the sale of ARCALYST reached $294.5 million for the nine months ended September 30, 2024, compared to $162.0 million for the same period in 2023, an increase of 81.6%[178]. Expenses - Research and development expenses for the three months ended September 30, 2024, were $26.1 million, up from $17.1 million in the same period of 2023, indicating a 52% increase[18]. - Selling, general, and administrative expenses for the three months ended September 30, 2024, were $46.4 million, compared to $34.5 million in the same period of 2023, representing a 34% increase[18]. - Total operating expenses for the nine months ended September 30, 2024, were $327.0 million, up from $212.1 million in 2023, reflecting a 54.1% increase[179]. - Research and development expenses rose to $76.4 million for the nine months ended September 30, 2024, compared to $56.0 million in 2023, marking a 36.4% increase[183]. - Collaboration expenses increased to $80.1 million for the nine months ended September 30, 2024, compared to $39.6 million in 2023, a rise of 102.5%[183]. Cash and Investments - Cash and cash equivalents at the end of the period were $97,376,000, down from $117,828,000 at the end of September 2023[22]. - The company had cash, cash equivalents, and short-term investments totaling $223,780 as of September 30, 2024, which is expected to fund operations for at least twelve months[33]. - As of September 30, 2024, total unrecognized compensation expense related to unvested share option awards was $42,841, expected to be recognized over a weighted average remaining period of 2.58 years[67]. - The company’s total cash equivalents and short-term investments as of September 30, 2024, included $48,429 in money market funds and $126,404 in U.S. Treasury notes[49]. Financing and Capital Requirements - The company may require substantial additional financing to further its operational plans, which may not be obtainable on acceptable terms[11]. - The company expects to incur significant expenses related to the commercialization of ARCALYST and the development of product candidates, including ongoing clinical trials[200]. - The company anticipates requiring additional capital for collaboration, licensing, or strategic transactions, as well as for product manufacturing and marketing[202]. - Existing cash, cash equivalents, and short-term investments are expected to fund operating expenses for at least the next 12 months[202]. Collaboration Agreements - The Company entered into a license agreement with Genentech, receiving an upfront payment of $80,000 and additional cash payments totaling $55,000 for development milestones in 2023 and early 2024[75]. - The Company is eligible for approximately $600,000 in contingent payments under the Genentech License Agreement, with about $570,000 remaining as of September 30, 2024[75]. - The Company recognized $5,261 in collaboration revenue under the Genentech License Agreement during the nine months ended September 30, 2024, with $4,989 related to prior performance obligations[81]. - The Company received a total upfront cash payment of $22,000 under the Huadong Collaboration Agreements, with potential payments of up to $70,000 for rilonacept and $576,000 for mavrilimumab[83]. Research and Development Focus - The company is focused on developing therapeutic medicines for underserved cardiovascular and autoimmune conditions, indicating a strategic emphasis on unmet medical needs[24]. - The company is currently enrolling and dosing a Phase 2b clinical trial of abiprubart in Sjögren's Disease, following positive results from earlier cohorts in rheumatoid arthritis trials[141]. - The company has exclusive worldwide rights to develop and commercialize mavrilimumab, with ongoing evaluations for potential partnership opportunities[141]. Risks and Uncertainties - The company faces numerous risks and uncertainties in the research and commercialization of biologic products, impacting future funding requirements[203]. - The company has made significant estimates regarding revenue recognition, research and development expenses, and deferred tax assets, which may differ from actual results[31]. - Critical accounting policies involve significant judgment, particularly in accrued research and development expenses, revenue recognition, and realizability of deferred tax assets[205].

| --- | --- | --- | --- | --- | |-------|-------|----------------------------|-------|-------| | | | | | | | | | Third Quarter 2024 | | | | | | | | | | | | Financial Results and | | | | | | Recent Portfolio Execution | | | OCTOBER 29, 2024 Agenda | --- | --- | |--------------------------------------------------------------------------------|-------| | Introduction \| Sanj K. Patel, Chief Executive Officer | | | | | | ARCALYST ® Commercial Execution \| Ross Moat, Chief Commercial Officer | | | | | | Third Qu ...

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman and Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Liisa Bayko - Evercore ISI Paul Choi - Goldman Sachs Eva Fortea-Verdejo - Wells Fargo David Nierengarten - Wedbush Se ...

Earnings Performance - Kiniksa Pharmaceuticals reported a quarterly loss of $0 18 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0 01, representing an earnings surprise of -1,700% [1] - The company's loss per share improved from $0 20 a year ago, showing a year-over-year improvement [1] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Revenue Performance - Kiniksa Pharmaceuticals posted revenues of $112 21 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1 77% [2] - This represents a significant increase from year-ago revenues of $67 05 million [2] - The company has topped consensus revenue estimates four times over the last four quarters [2] Stock Performance - Kiniksa Pharmaceuticals shares have added about 57 3% since the beginning of the year, outperforming the S&P 500's gain of 22 1% [3] - The stock's immediate price movement will depend on management's commentary on the earnings call [3] Earnings Outlook - The current consensus EPS estimate is $0 02 on $119 26 million in revenues for the coming quarter and -$0 29 on $418 02 million in revenues for the current fiscal year [7] - The estimate revisions trend for Kiniksa Pharmaceuticals is favorable, translating into a Zacks Rank 2 (Buy) [6] Industry Context - Kiniksa Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry, which is currently in the top 30% of the 250 plus Zacks industries [8] - The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8] Peer Comparison - Affimed N V, another stock from the same industry, is expected to post a quarterly loss of $1 14 per share, representing a year-over-year improvement of +32 9% [9] - Affimed N V's revenues are expected to be $1 41 million, down 34 4% from the year-ago quarter [9]

Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution – ARCALYST (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMYAward-winning singer-songwriter, Carly Pearce – – Kiniksa exp ...

– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $410 - $420 million –– Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY® Award-winning singer-songwriter, Carly Pearce –– Kiniksa expects to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET to ...

LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upo ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. - ...